期刊文献+

硝酸异山梨酯制剂释放NO的质量控制分析 被引量:2

Quality Control of Releasing NO via Isosorbide Dinitrate
下载PDF
导出
摘要 分析机体内一氧化氮(NO)来源、作用和双向性,探索了硝酸异山梨酯释放NO基本过程、生产工艺和质量控制对策,归纳整理了硝酸异山梨酯制剂质量控制的发展趋势;研究采用文献分析和生产企业调查结合方法;研究获得了硝酸异山梨酯释放NO的质量状况与溶出度、亚硝酸盐与硝酸盐含量、渗透压、原料纯度、有关物质控制、辅料、残留溶剂、储运条件和违法添加密切相关信息,提出了提高药品质量标准,优化处方、改进工艺,严格储运管理,加强生产监管理和开展专项检查的防治对策;研究结论认为硝酸异山梨酯释放NO质量控制点是生产过程,控制对策源于质量分析. This paper analyses source,function and double-edged sword of NO in vivo; explores the basic process,production engineering and quality control measures,and summarizes the development trend of quality control for releasing NO via isosorbide dinitrate by means of literature analysis and survey methods for production enterprises. The quality of releasing NO viaisosorbide dinitrate was related to dissolution rate,nitrite and nitrate content,osmotic pressure,purity of raw materials,auxiliary materials,related substances ontrol,residual solvents,storageconditions,and illegal addition. Some prevention and control measures are put forward to improve the uality standard of drugs. They are the optimization of prescription,improving process,strict supervision for storage and transportation,and carried out special inspections. The conclusions of this study are that the quality control of releasing NO via isosorbide dinitrate is the production process and the control measures derives from quality analysis.
出处 《吉林化工学院学报》 CAS 2015年第6期22-27,共6页 Journal of Jilin Institute of Chemical Technology
基金 吉林省科技发展支撑计划中药和生物药重点项目(No.20120946) 吉林化工学院博士基金项目(No.20120121)资助
关键词 硝酸异山梨脂 NO 释放 控制对策 isosorbide dinitrate NO release control measures
  • 相关文献

参考文献34

  • 1Zhou, L. , Zhu, D. Y. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clini- cal implications [ J ]. Nitric Oxide, 2009,20,223-230.
  • 2Burkard, N. , Rokita, A. G. , Kaufmann, S. G. , et al. Conditional neuronal nitric oxide synthase overexpres- sion impairs myocardial contractility [ J ]. Circ. Res. , 2007,100 : e32-e44.
  • 3Peluffo, R. D. L Arginine currents in rat cardiac ven- tricular myocytes [ J ]. J Physiol, 2007,580 : 925-936.
  • 4Gassanov, N. , Jankowski, M. , Danalache, B. , et al. Ar- ginine vasopressin mediated cardiac differentiation:in- sights into the role of its receptors and nitric oxide sig- naling[ J ]. J Biol Chem ,2007,282 : 11255-11265.
  • 5Guix,F. X. ,Uribesalgo,I. ,Coma,M. ,et al. The physiolo- gy and pathophysiology of nitric oxide in the brain [ J ]. Prog Neurobio1,2005,76,126-152.
  • 6Barouch, L. A. , Harrison, R. W. , Skaf, M. W. , et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms [ J ]. Nature, 2002, 416:337-339.
  • 7Palmer, R. M. , Ferrige, A. G. , Moncada, S. Nitric ox- ide release accounts for the biological activity of endo- thelium-derived relaxing factor [ J ]. Nature. 1987,327 : 524-6.
  • 8West, A. R. , Tseng, K. Y. Nitric oxide-soluble guanylyl cyclase-cyclic GMP signaling in the striatum: new tar- gets for the treatment of Parkinson' s disease [ J ]. Front Syst Neurosci, 2011,5 : 1-9.
  • 9Krumenaeker, J. S. , Katsuki, S. , Kots, A. , et al. Differ- ential expression of genes involved in eGMP dependent nitric oxide signaling in murine embryonic stem (ES) cells and ES cell derived cardiomyocytes [ J ]. Nitric Oxide, 2006,14 : 1-11.
  • 10Carvajal,J. A. , Germain, A. M. , Huidobro Toro, J. P. , et al. Molecular mechanism of cGMP mediated smooth muscle relaxation [ J ]. J Cell Physiol, 2000, 184: 409-420.

同被引文献36

  • 1Camont L,Cottart C H,Rhayem Y,et al.Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions[J].Anal.Chim.Acta,2009,634:121-128.
  • 2Mikulski D,Gorniak R,Molski M.A theoretical study of the structure-radical scavenging activity of transresveratrol analogues and cis-resveratrol in gas phase and water environment[J].Eur.J.Med.Chem.,2010,45:1015-1027.
  • 3Neves A R,Lucio M,Lima J L.Resveratrol in medicinal chemistry:a critical review of its pharmacokinetics,drug-delivery,and membrane interactions[J].Curr.Med.Chem.,2012,19:1663-1681.
  • 4Baur J A,Sinclair D A.Therapeutic potential of resveratrol:the in vivo evidence[J].Nat.Rev.Drug Discovery,2006,5:493-506.
  • 5Basly J P,Marre-Fournier F,Le Bail J C.Estrogenic/antiestrogenic and scavenging properties of(E)-and(Z)-resveratrol[J].Life Sci.,2000,66:769-777.
  • 6Catalgol B,Batirel S,Taga Y.et al.Resveratrol:French paradox revisited[J].Front.Pharmacol.,2012,3:141.
  • 7Baur J A,Sinclair DA.Therapeutic potential of resveratrol:the in vivo evidence[J].Nat.Rev.Drug Discov.,2006(5):493-506.
  • 8Calabrese E J.Resveratrol:an assessment of its dose response an introduction[J].Hum.Exp.Toxicol.,2010,29:977-979.
  • 9Gescher A J.Resveratrol from red grapes-pedestrian polyphenol or useful anticancer agent[J].Planta Med.,2008,74:1651-1655.
  • 10Bradamante S,Barenghi L,Villa A.Cardiovascular protective effects of resveratrol[J].Cardiovasc.Drug Rev.,2004,22,169-188.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部